Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Willow Biosciences

DB:3D7
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3D7
DB
€32M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Willow Biosciences Inc., a biotechnology company, produces plant derived compounds for the pharmaceutical, health and wellness, and consumer packaged goods industries. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Willow Biosciences has significant price volatility in the past 3 months.
3D7 Share Price and Events
7 Day Returns
3.5%
DB:3D7
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:3D7
-7.4%
DE Biotechs
-14.2%
DE Market
3D7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Willow Biosciences (3D7) 3.5% -15.3% -24% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 3D7.
  • No trading data on 3D7.
Price Volatility
Industry
5yr Volatility vs Market

3D7 Value

 Is Willow Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Willow Biosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Willow Biosciences.

DB:3D7 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:3D7
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 26.5%) (2.43%))
1.045
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.045 * 5.44%)
5.29%

Discounted Cash Flow Calculation for DB:3D7 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Willow Biosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:3D7 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 5.29%)
2020 -11.00 Analyst x1 -10.45
2021 -2.00 Analyst x1 -1.80
2022 1.00 Analyst x1 0.86
2023 1.48 Est @ 47.59% 1.20
2024 1.97 Est @ 33.2% 1.52
2025 2.42 Est @ 23.12% 1.78
2026 2.81 Est @ 16.07% 1.96
2027 3.12 Est @ 11.13% 2.07
2028 3.36 Est @ 7.67% 2.11
2029 3.54 Est @ 5.26% 2.11
Present value of next 10 years cash flows CA$1.00
DB:3D7 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$3.54 × (1 + -0.39%) ÷ (5.29% – -0.39%)
CA$62.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$62.02 ÷ (1 + 5.29%)10
CA$37.03
DB:3D7 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$1.00 + CA$37.03
CA$38.03
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$38.03 / 78.89
CA$0.48
DB:3D7 Discount to Share Price
Calculation Result
Exchange Rate CAD/EUR
(Reporting currency to currency of DB:3D7)
0.657
Value per Share
(EUR)
= Value per Share in CAD x Exchange Rate (CAD/EUR)
= CA$0.48 x 0.657
€0.32
Value per share (EUR) From above. €0.32
Current discount Discount to share price of €0.30
= -1 x (€0.30 - €0.32) / €0.32
5.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Willow Biosciences is available for.
Intrinsic value
6%
Share price is €0.298 vs Future cash flow value of €0.31661
Current Discount Checks
For Willow Biosciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Willow Biosciences's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Willow Biosciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Willow Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Willow Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3D7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.62
DB:3D7 Share Price ** DB (2020-04-08) in EUR €0.3
DB:3D7 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.522 CA$0.45
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Willow Biosciences.

DB:3D7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:3D7 Share Price ÷ EPS (both in CAD)

= 0.45 ÷ -0.62

-0.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Willow Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Willow Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Willow Biosciences's expected growth come at a high price?
Raw Data
DB:3D7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Willow Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Willow Biosciences's assets?
Raw Data
DB:3D7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.28
DB:3D7 Share Price * DB (2020-04-08) in EUR €0.3
DB:3D7 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.522 CA$0.45
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:3D7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:3D7 Share Price ÷ Book Value per Share (both in CAD)

= 0.45 ÷ 0.28

1.63x

* Primary Listing of Willow Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Willow Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Willow Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Willow Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

3D7 Future Performance

 How is Willow Biosciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69.2%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Willow Biosciences expected to grow at an attractive rate?
  • Unable to compare Willow Biosciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Willow Biosciences's earnings growth to the Germany market average as no estimate data is available.
  • Willow Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:3D7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3D7 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 69.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3D7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3D7 Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 98 1
2023-12-31 41 1
2022-12-31 16 1 1
2021-12-31 1 -2 1
2020-12-31 0 -11 1
DB:3D7 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -9 -45
2019-09-30 0 -5 -42
2019-06-30 0 -3 -41
2019-03-31 0 -2 -2
2018-12-31 0 -1 -2
2018-09-30 0 -1 -2
2017-12-31 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Willow Biosciences is high growth as no earnings estimate data is available.
  • Willow Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3D7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Willow Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3D7 Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
DB:3D7 Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.62
2019-09-30 -0.79
2019-06-30 -1.21
2019-03-31 -0.11
2018-12-31 -0.75
2018-09-30 -1.09
2017-12-31 -1.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Willow Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Willow Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Willow Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

3D7 Past Performance

  How has Willow Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Willow Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Willow Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Willow Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Willow Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Willow Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Willow Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3D7 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.00 -44.57 8.24 2.67
2019-09-30 0.01 -41.62 5.41 1.55
2019-06-30 0.02 -40.80 3.65 0.21
2019-03-31 0.02 -1.73 1.61 0.07
2018-12-31 0.02 -1.64 1.55 0.07
2018-09-30 0.01 -2.28 2.03 0.22
2017-12-31 -1.55 1.52
2016-12-31 -1.10 1.07
2015-12-31 -4.46 4.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Willow Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Willow Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Willow Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Willow Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Willow Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

3D7 Health

 How is Willow Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Willow Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Willow Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Willow Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Willow Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Willow Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Willow Biosciences Company Filings, last reported 3 months ago.

DB:3D7 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 22.01 0.00 19.94
2019-09-30 24.73 0.00 24.57
2019-06-30 24.85 0.00 30.14
2019-03-31 0.37 0.21 0.09
2018-12-31 0.84 0.00 0.44
2018-09-30 0.98 0.00 0.84
2017-12-31 0.25 0.00 0.61
2016-12-31 0.11 0.00 0.07
2015-12-31 1.10 0.00 1.08
  • Willow Biosciences has no debt.
  • Willow Biosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Willow Biosciences has sufficient cash runway for 1.3 years based on current free cash flow.
  • Unable to confirm if Willow Biosciences has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Willow Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Willow Biosciences has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

3D7 Dividends

 What is Willow Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Willow Biosciences dividends.
If you bought €2,000 of Willow Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Willow Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Willow Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3D7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3D7 Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Willow Biosciences has not reported any payouts.
  • Unable to verify if Willow Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Willow Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Willow Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Willow Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Willow Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Willow Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

3D7 Management

 What is the CEO of Willow Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Trevor Peters
AGE 42
TENURE AS CEO 1 years
CEO Bio

Mr. Trevor Anthony Peters serves as President and Chief Executive Officer at Willow Biosciences Inc. since April 12, 2019. He also serves as Director at Willow Biosciences Inc. since April 12, 2019. He serves as Director at Gegs Capital Corp. since April 25, 2018. Mr. Peters serves as President and Chief Executive Officer of Torenco Energy Inc., a company focused on business development in upstream oil and gas. Mr. Peters has been the Chief Financial Officer of Caracal Energy Inc. (formerly Griffiths Energy International Inc.) since July 1, 2011. He co-founded Waseca Energy Inc and served as its and Vice President of Business Development. He serves as Director, Chief Financial Officer and Corporate Secretary at Global Investments Capital Corp. Mr. Peters has been Director at Octant Energy Corp. since March 8, 2017. He served as Vice President of Corporate Planning & Business Development at Orion Oil & Gas Corporation of Sprott Resource Corp. since January 1, 2008. He served as Vice President of Business Development for Orion Oil& Gas Corporation. He served as Manager of Corporate Planning at North American Oil Sands. After its sale, he served as the President of his own consulting firm, Tritonia Holdings Ltd from July 2007 to October 2009. Mr. Peters served as a Director of Capita Markets - North at American Oil Sands Corporation from January 2006 to June 2007. He was a Senior Analyst at TSC Company Ltd. from September 2004 to December 2005. Mr. Peters holds Bachelor of Mathematics (Honours) from the University of Waterloo.

CEO Compensation
  • Insufficient data for Trevor to compare compensation growth.
  • Insufficient data for Trevor to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Willow Biosciences management team in years:

1
Average Tenure
48
Average Age
  • The average tenure for the Willow Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Trevor Peters

TITLE
President
AGE
42
TENURE
1 yrs

Travis Doupe

TITLE
Chief Financial Officer
AGE
48
TENURE
1 yrs

Peter Facchini

TITLE
Chief Scientific Officer
AGE
55
TENURE
1 yrs

Troy Talkkari

TITLE
Vice President of Corporate Development
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Willow Biosciences board of directors in years:

1
Average Tenure
57
Average Age
  • The average tenure for the Willow Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Seufer-Wasserthal

TITLE
Independent Chairman
AGE
57
TENURE
0.2 yrs

Trevor Peters

TITLE
President
AGE
42
TENURE
1 yrs

Sadiq Lalani

TITLE
Independent Director
TENURE
1 yrs

Al Foreman

TITLE
Director
TENURE
1 yrs

Don Archibald

TITLE
Independent Director
AGE
58
TENURE
1 yrs

Fotis Kalantzis

TITLE
Independent Director
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Willow Biosciences individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Feb 20 Buy Travis Doupe Individual 20. Feb 20 20. Feb 20 25,000 €0.48 €11,878
05. Dec 19 Buy Sadiq Lalani Individual 29. Nov 19 29. Nov 19 50,000 €0.42 €21,169
06. Nov 19 Buy Travis Doupe Individual 05. Nov 19 05. Nov 19 20,000 €0.47 €9,328
04. Nov 19 Buy Sadiq Lalani Individual 04. Nov 19 04. Nov 19 50,000 €0.49 €24,582
31. Oct 19 Buy Trevor Peters Individual 31. Oct 19 31. Oct 19 50,000 €0.50 €25,225
28. Oct 19 Buy Trevor Peters Individual 28. Oct 19 28. Oct 19 50,000 €0.52 €26,227
25. Oct 19 Buy Sadiq Lalani Individual 22. Oct 19 25. Oct 19 110,000 €0.52 €52,512
21. Oct 19 Buy Travis Doupe Individual 18. Oct 19 18. Oct 19 15,000 €0.43 €6,459
15. Aug 19 Buy Trevor Peters Individual 14. Aug 19 14. Aug 19 9,000 €0.50 €4,489
14. Aug 19 Buy Sadiq Lalani Individual 14. Aug 19 14. Aug 19 20,000 €0.49 €9,707
13. Aug 19 Buy Trevor Peters Individual 29. Jul 19 07. Aug 19 13,000 €0.57 €6,860
02. Aug 19 Buy Sadiq Lalani Individual 01. Aug 19 01. Aug 19 20,000 €0.47 €9,309
31. Jul 19 Buy Troy Talkkari Individual 30. Jul 19 30. Jul 19 25,000 €0.58 €14,560
31. Jul 19 Buy Sadiq Lalani Individual 31. Jul 19 31. Jul 19 20,000 €0.51 €10,254
29. Jul 19 Buy Trevor Peters Individual 12. Jul 19 29. Jul 19 20,500 €0.60 €11,890
12. Jul 19 Buy Trevor Peters Individual 09. Jul 19 11. Jul 19 50,000 €0.68 €31,064
08. Jul 19 Buy Trevor Peters Individual 02. Jul 19 04. Jul 19 30,000 €0.80 €23,656
27. Jun 19 Buy Trevor Peters Individual 26. Jun 19 26. Jun 19 20,000 €0.82 €16,336
24. Apr 19 Buy Sadiq Lalani Individual 12. Apr 19 12. Apr 19 7,000,000 €0.02 €162,436
X
Management checks
We assess Willow Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Willow Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

3D7 News

Simply Wall St News

3D7 Company Info

Description

Willow Biosciences Inc., a biotechnology company, produces plant derived compounds for the pharmaceutical, health and wellness, and consumer packaged goods industries. It primarily focuses on the production of cannabinoids for the treatment for pain, anxiety, obesity, cancer, and brain disorders. The company has a Joint Development Agreement with Noramco, Inc. to develop and commercialize a yeast-based production platform for the manufacturing and distribution of cannabidiol (CBD). It operates in Burnaby, British Columbia and Mountain View, California. Willow Biosciences Inc. is headquartered in Calgary, Canada.

Details
Name: Willow Biosciences Inc.
3D7
Exchange: DB
Founded:
€32,345,670
78,891,879
Website: http://www.willowbio.com
Address: Willow Biosciences Inc.
3655 36th Street NW,
Calgary,
Alberta, T2L 1Y8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB 3D7 Common Shares Deutsche Boerse AG DE EUR 15. Apr 2019
Number of employees
Current staff
Staff numbers
42
Willow Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:43
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.